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Background: Diabetes mellitus is an increasingly prevalent metabolic disorder that is associated with substantial
disease burden. Australia has an opportunity to improve ways of caring for the growing number of people with
diabetes, but this may require changes to the way care is funded, organised and delivered. To inform how best to
care for people with diabetes, and to identify the extent of change that is required to achieve this, the Diabetes
Care Project (DCP) will evaluate the impact of two different, evidence-based models of care (compared to usual
care) on clinical quality, patient and provider experience, and cost.
Methods/Design: The DCP uses a pragmatic, cluster randomised controlled trial design. Accredited general
practices that are situated within any of the seven Australian Medicare Locals/Divisions of General Practice that
have agreed to take part in the study were invited to participate. Consenting practices will be randomly assigned to
one of three treatment groups for approximately 18 to 22 months: (a) control group (usual care); (b) Intervention 1
(which tests improvements that could be made within the current funding model, facilitated through the use of an
online chronic disease management network); or (c) Intervention 2 (which includes the same components as
Intervention 1, as well as altered funding to support voluntary patient registration with their practice, incentive
payments and a care facilitator). Adult patients who attend the enrolled practices and have established
(≥12 month’s duration) type 1 diabetes mellitus or newly diagnosed or established type 2 diabetes mellitus are
invited to participate. Multiple outcomes will be studied, including changes in glycosylated haemoglobin (primary
outcome), changes in other biochemical and clinical metrics, incidence of diabetes-related complications, quality of
life, clinical depression, success of tailored care, patient and practitioner satisfaction, and budget sustainability.
Discussion: This project responds to a need for robust evidence of the clinical and economic effectiveness of
coordinated care for the management of diabetes in the Australian primary care setting. The outcomes of the study
will have implications not only for diabetes management, but also for the management of other chronic diseases,
both in Australia and overseas.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12612000363886); World Health
Organisation (U1111-1128-0481).
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Diabetes mellitus is a chronic metabolic disorder that
poses a significant health care problem in both developed
and developing countries around the world, including
Australia. An estimated 366 million people are affected
by diabetes worldwide, and the incidence and preva-
lence of diabetes continues to rise, with more than 552
million people expected to be affected by the disorder
by 2030—an increase of 51 percent [1]. People with dia-
betes are at risk of developing a range of complications,
including chronic renal disease, diabetic eye disease and
cardiovascular disease [2]. The impact of diabetes on
the health system is considerable (in terms of both fi-
nancial and human resources), with four percent of hos-
pitalisations, 3.7 percent of general practitioner visits
and 7.2 million prescriptions in Australia in 2009–10 at-
tributed to the condition [3]. Direct and indirect health
care costs related to the management of diabetes in
Australia were estimated at AU$3.1 billion (excluding
Commonwealth benefits) for type 2 diabetes (in 2001–02)
[4], and at least $430 million for type 1 diabetes (in
2004–05) [5]. The chronicity and prevalence of diabetes,
and the complications associated with the disorder,
mean that diabetes will become an increasingly large
burden on the health system, and on society, if new and
more effective ways to manage it are not identified.
Australia has a unique opportunity to find better ways
of caring for people with diabetes. Despite clear clinical
objectives, fewer than fifty percent of people diagnosed
with diabetes achieve the recommended targets for gly-
cosylated haemoglobin, blood pressure and blood lipids
[6-11]. Although care planning has been shown to result
in substantial improvements in clinical and process out-
comes for people with diabetes [12], almost eighty percent
of GPs believe that the current care planning system in-
volves too much red tape [13]. As a result, only eighteen
percent of people with diabetes complete the recom-
mended annual cycle of care [14], and approximately
seventy percent do not have a multidisciplinary care
plan at all [15].
To inform how best to care for people with diabetes,
and to identify the extent of change that is required to
achieve this, the Australian Government established the
Diabetes Care Project (DCP)—a three-year, cluster ran-
domised controlled trial that will test the impact of two
different models of care (in comparison with usual care)
on clinical quality and patient and provider experience.
These models of care are designed to evaluate a number
of evidence-based changes that the National Health and
Hospital Reform Commission (NHHRC) [16] and the
National Diabetes Advisory Group have identified as hav-
ing the potential to improve the way care is organised
and delivered. These changes include: (1) the introduc-
tion of new funding models, such as the NHHRC’srecommendation to link funding with a health care
home (i.e., a single primary health care service that
people with chronic disease would voluntarily register
with to ‘help to coordinate, guide and navigate access to
the right range of multidisciplinary health service pro-
viders’); [16] (2) offering financial incentives to improve
the quality of health care services; [17] (3) facilitating im-
proved communication and information-sharing across
multidisciplinary health services through the use of elec-
tronic health records; (4) changing the way the primary
health care team work together (e.g., by introducing a care
facilitator and making case conferences easier to organise);
[18] and (5) allowing practices to more easily review their
performance and make any necessary adjustments.
Intervention 1 of the DCP tests improvements that
could be made within the current funding model and
focuses on information, communication and education.
Intervention 2 includes the same components as Interven-
tion 1, as well as altered funding to support voluntary
patient registration with practices (‘health care homes’),
incentive payments and funding for a care facilitator. The
objective of the trial is to compare the impact of these two
interventions on clinical quality and patient and provider
experience, and to determine if the interventions allow
care to be provided in more flexible ways. The DCP also
seeks to determine if these interventions are economically
sustainable and scalable nationally. The findings from this
project will be used to make recommendations for health
policy changes in Australia.
Methods/Design
Study design
The Diabetes Care Project is a pragmatic, cluster rando-
mised controlled trial with three parallel arms. Clustering
is at the level of the general practice. A cluster design is
used to minimise contamination between intervention
and control participants.
Research objectives
The project is designed to: (1) evaluate the impact of the
two interventions (in comparison with usual care) on
clinical outcomes in adults with diabetes mellitus, patient
quality of life, continuity of care, multidisciplinary collab-
oration and interaction, and patient and provider satisfac-
tion and empowerment; (2) determine if the interventions
allow care to be provided in more flexible ways; and
(3) determine whether the interventions are scalable
nationally and economically sustainable.
Recruitment
Seven Medicare Locals/Divisions of General Practice
(independent entities that are responsible for coordinating
local primary health care services) [19] across the states of
Queensland (n = 4), South Australia (n = 2), and Victoria
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commencement of the trial, each Medicare Local/Division
of General Practice distributes study information sheets to
all general practices (clusters) within their network and
seeks expressions of interest to participate in the trial.
Practices that express an interest in participating in the
trial are enrolled in the project and randomly assigned to
one of three treatment groups: control group, Intervention
1 or Intervention 2 (Figure 1). It is expected that fifty gen-
eral practices will be enrolled in each group. Each enrolled
practice is required to undergo training to familiarise
themselves with the assigned intervention and study pro-
cedures. Medicare Locals/Divisions of General Practice
that are assigned to Intervention 2 are supported by a ‘trial
delivery and integration team’ to recruit and train care
facilitators.
All eligible patients with diabetes are identified by the
enrolled practice and the trial delivery and integration
team and sent a GP-endorsed letter advertising the trial
and actively seeking enrolments. A participant information
sheet and all relevant consent forms are enclosed with this
letter. A follow-up telephone call is made to all patients
(either by the care facilitator, practice nurse or Medicare
Local/Division of General Practice support person) to en-
courage participation and answer questions. After receiv-
ing informed consent, participants are asked to complete
the baseline surveys and to meet with their GP to have
their baseline metrics recorded. Participant recruitment
commenced in April 2012, and patient participation will
be completed by February 2014. The planned end date for
the trial is June 2014.
Randomisation
In four of the Medicare Locals/Divisions of General
Practice, enrolled general practices are randomly allo-
cated to the control group or Intervention 1 at a ratio of
1:2. In the other three Medicare Locals/Divisions of
General Practice, practices are randomly assigned to the
control group or Intervention 2 at a ratio of 1:2. A single
type of intervention is tested in each Medicare Local/
Division of General Practice as a result of two practical
constraints: (1) care facilitators included in Intervention
2 are required to work with four or five practices within
a single geographic area in order to work effectively; and
(2) Medicare Locals/Divisions of General Practice would
find it difficult to enrol and support practices using
two different interventions, given that Intervention 1 and
Intervention 2 comprise multiple components. Random-
isation is applied after recruiting each group of three prac-
tices in a combined Medicare Local/Division of General
Practice and Region stratum, where Region refers to urban
or rural area. This helps to mitigate the potential bias cre-
ated by testing only one intervention in each Medicare
Local/Division of General Practice. Randomisation isapplied separately for urban and rural practices within
each Medicare Local/Division of General Practice because
it is expected that service use and availability will differ
by region. To approximate equality of sample sizes in
each group, block randomisation is used with computer-
generated, randomly permuted blocks of three. A re-
searcher who is not involved in the implementation of
the project and is blinded to the identity of the prac-
tices performs this task.
Study population
Practice inclusion criteria
All practices situated within the Medicare Locals/Divisions
of General Practice that have agreed to take part in the
study (located in South Australia, Queensland and
Victoria, Australia) are offered an opportunity to par-
ticipate in the project, conditional on meeting the fol-
lowing criteria: (1) the practice has not indicated that
they will not participate in trials; (2) practice software
(GPs’ desktop application) is compatible with project
software for data extraction purposes; (3) the practice
meets the Royal Australian College of General Practi-
tioners (RACGP) definition of ‘general practice’; (4) the
practice is accredited (or registered for accreditation)
against the current edition of the RACGP ‘Standards for
general practices’; (5) the practice has current public liabil-
ity insurance; and (6) all health professionals at the prac-
tice who will be providing care to enrolled patients are
appropriately qualified and registered, and have current
professional indemnity insurance. Most general practices
meet these criteria.
Participant inclusion criteria
Adult patients of participating general practices are eli-
gible to participate in the trial if they meet the following
criteria: (1) they are aged 18 years or older; (2) they have
established (≥12 months duration) type 1 diabetes mellitus
or newly diagnosed or established type 2 diabetes melli-
tus; and (3) they have the capacity to provide informed
consent to participate.
Participant exclusion criteria
Patients are excluded from the study if one or more of
the following criteria are present: (1) they have a terminal
illness with a life expectancy of less than two years; (2)
they have dementia; (3) they are pregnant or planning to
become pregnant in the next two years; and (4) they
are participating in the Coordinated Veterans Care (CVC)
program.
Interventions
Each general practice (cluster) is randomly assigned to
one of the three treatment arms. Participants in the
Figure 1 Flow chart of Diabetes Care Project.
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practices will continue to provide care as usual.
Practices assigned to Intervention 1 experience two
changes: access to an online chronic disease manage-
ment network (cdmNet) and access to training and cap-
ability building. The cdmNet decision support service is
instrumental in generating, updating and reviewing
multidisciplinary care plans; facilitating communication
between team members; sharing patient information;
engaging patients in their care; and facilitating ser-
vice payments. The care plans generated by cdmNet in
Intervention 1 are pre-populated with the minimum
care requirements for the general diabetes population,
as informed by best practice guidelines and recom-
mended treatments for any recognised comorbidities.
CdmNet also generates population-level clinical status
reports that allow GPs to proactively manage their
population of people with diabetes enrolled in the trial.
The training and capability building has three main
functions: to assist practices in implementing the new
model of care and cdmNet; to provide regular access to
endocrinologists/diabetologists; and to provide a forum
where practices can find out about new developments
in diabetes care and share their experiences with other
trial participants.Figure 2 Overview of risk stratification categories#. HbA1c = Glycosylat
categories apply to participants with type 2 diabetes. Participants diagnose
resources as persons in the ‘out-of-range/complex’ category. Newly diagno
plus additional support for introductory needs.Practices assigned to Intervention 2 experience four
changes: access to cdmNet; altered funding arrangements;
the provision of a care facilitator; and access to training
and capability building. Coordinated care is facilitated
through the use of the cdmNet decision support service
(as in Intervention 1), but with the addition of risk stratifi-
cation. Patients are stratified into one of four risk categor-
ies based on whether they have complications associated
with diabetes (e.g., peripheral neuropathy, background dia-
betic retinopathy, foot ulceration) and whether their dia-
betes is under control (uncontrolled diabetes requiring
additional allied health services is defined as either
HbA1c >7.5% [>58.5 mmol/mol], systolic blood pressure
>150 mmHg, total serum cholesterol >5.0 mmol/l, or sys-
tolic blood pressure >140 mmHg plus total serum choles-
terol >4.5 mmol/l). The four risk categories are
characterised as follows: (1) not complex and within range;
(2) complex and within range; (3) not complex and out of
range; and (4) complex and out of range (see Figure 2).
The care plan that is generated for the patient reflects the
minimum care needs of individuals in their respective
strata, as informed by best practice guidelines. Care in
Intervention 2 is also coordinated through the provision
of a full-time care facilitator (a tertiary-qualified health
professional with experience in primary health careed haemoglobin; SBP = Systolic blood pressure. #These risk stratification
d with type 1 diabetes will be provided with the same level of
sed patients will receive the support designated from their category
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team in delivering care in accordance with the agreed care
plan. The care facilitator has a case load of approximately
300 to 400 patients across all four risk strata.
The altered funding arrangements that are tested in
Intervention 2 comprise three components: flexible
funding for general practices; pay-for-performance pay-
ments for general practices; and flexible funding for allied
health professionals. Flexible funding for general practices
provides upfront, lump sum funding for all patients who
are voluntarily enrolled in the trial at a given practice,
which is adjusted according to the risk of the patient
population. This funding is used to fund care planning
activities for those patients who require it (and is paid
once a patient is enrolled rather than for completion of
any specific activities) but it does not replace usual GP
consultation fees covered by Medicare (Australia’s univer-
sal healthcare system). Pay-for-performance payments
reward practices for improvements in patient clinical
outcomes, meeting pre-defined levels of positive patient
experience and completing pre-defined clinical pro-
cesses. Flexible funding for allied health professionals is
accessed on a fee-for-service basis, drawing on a risk-
adjusted allowance for each patient. Participants in the
control group, Intervention 1 and Intervention 2 will re-
ceive their respective care for a period of approximately
18 to 22 months (depending on when they are risk
stratified).
Outcome measures
Primary outcome
The primary endpoint is the difference in the change in
HbA1c between groups. The study is powered to detect a
difference of at least 0.25 percentage points in mean
HbA1c between any two treatment groups. This differ-
ence is considered clinically significant on an intention-
to-treat basis [20]. HbA1c data is collected by practice
staff, as directed by the care plan, and recorded in
cdmNet.
Secondary outcomes
Secondary outcomes include: changes in other bio-
chemical and clinical metrics (specifically serum total
cholesterol, serum triglycerides, serum low-density
lipoprotein cholesterol, serum high-density lipoprotein
cholesterol, estimated glomerular filtration rate and
albumin:creatinine ratio, blood pressure, body mass
index and waist circumference, as recorded in the GP
patient record or patient’s local pathology laboratory);
incidence of diabetes-related complications (specifically
autonomic and peripheral neuropathy, peripheral arterial
disease, diabetic foot ulceration, lower limb amputation,
microalbuminuria, chronic kidney disease, proliferative
and non-proliferative diabetic retinopathy, glaucoma,serious vision loss, acute state of severe uncontrolled
diabetes requiring hospitalisation, myocardial infarction,
stable and unstable angina, trans-ischaemic attack, cere-
brovascular accident and sexual dysfunction); health-
related quality of life (measured by the Assessment of
Quality of Life - 4 Dimension [AQoL-4D] instrument);
clinical depression (measured by the Patient Health
Questionnaire); success of tailored care (assessed by the
practitioner satisfaction survey, Patient Evaluation of the
Quality of Diabetes Care survey, patient semi-structured
interviews and practitioner focus groups); and economic
sustainability (e.g., cost utility analysis). All outcomes are
measured at baseline and will be measured again at the
end of the trial (in approximately 18 to 22 months).
Secondary outcome data will be sourced from patient
and practitioner surveys (as outlined above), a patient
diary, patient semi-structured interviews, practitioner
focus groups, selected sections of the GP patient record
imported into cdmNet, the Medicare Australia database
(for Pharmaceutical Benefits Scheme and Medicare Bene-
fits Scheme data), the National Diabetes Supply Scheme
(NDSS) database, and hospital separation databases of the
Queensland, Victorian and South Australian Departments
of Health.
Sample size calculation
A minimum sample size of 150 practices (or 50 practices
per trial arm) and 3,750 patients (or 1,250 patients per
trial arm) would allow a difference of 0.25 percentage
points of HbA1c to be detected between any two trial
arms with 80 percent power. The sample size is based a
standard deviation of HbA1c of 1.4 percent, 20 percent
attrition over 18 months, a design effect of 3.45 based
on an ICC of 0.05 (correlation between baseline and 18-
month HbA1c), and a two-sided alpha level set at 0.025
to adjust for pairwise comparisons.
Statistical analysis
Main analysis
Descriptions of participants’ baseline characteristics (e.g.,
demographic data, comorbidities and clinical metrics) will
be reported by treatment group. Categorical variables
will be summarised by frequencies and percentages.
Continuous variables will be summarised by means and
SEMs, or non-parametric equivalents. All primary statis-
tical analyses will be performed on an intention-to-treat
basis. The continuous variable—HbA1c at approximately
18 to 22 months—will be compared between groups using
a linear mixed effect model with adjustment for clustering
and stratification status (Medicare Local/Division of Gen-
eral Practice and metro/rural practice location). The time/
group interaction parameter will be used to formally test
for an intervention effect. Secondary outcomes (excluding
economic sustainability and value for money) will be
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cordance with the reporting requirements outlined in the
Consolidated Standards of Reporting Trials (CONSORT)
statement - extension for cluster randomised trials [21].
Economic evaluation
Economic sustainability will be assessed by estimating
the total mean per patient cost (including co-payment)
and cost to government (separately for the Common-
wealth and State governments) of patients in each of the
three treatment groups. This will allow the DCP to esti-
mate cost and budget impacts of the intervention
models. Data will be sourced from Medicare Australia,
State governments (for hospital in-patient, emergency
and outpatient services), the patient diary and the
NDSS. Depending on how well participants are matched
across groups at baseline, some statistical adjustment
may be necessary. Each person will be allocated to a dia-
betes disease stage (based on risk and morbidity profile),
and the mean annual cost at each disease stage will be
estimated across all three groups. The rate of progres-
sion in disease stage over the course of the study will be
described for each patient and compared across groups
to test for any between-group differences. If differences
are detected, this will be used to model the downstream
cost and budget implications of the three models of
care.
A cost utility analysis will be conducted using the
AQoL-4D to derive quality of life utility scores and to
measure any change across the trial. Results for the
three groups will be compared to identify any differential
change in quality of life that can be multiplied by time
to generate quality-adjusted life year (QALY) gain or loss
for each intervention group. A quality of life utility score
will be calculated for each disease stage (from persons in
the disease stage), with a lower quality of life expected
with more advanced disease. If a difference in the rate of
disease progression is identified, this will be used to
model the downstream impact on QALYs. The cost of
implementing the model will be derived from trial
administrative data and health care costs as described
above. These costs will be combined with QALYs (within
the trial and modelled beyond the trial) to estimate cost
per QALY gain if it is found that the intervention is
more expensive but delivers greater quality of life.
Ethical considerations
The study protocol was approved by the human research
ethics committees of the Department of Health and
Ageing (Australian Government), Department of Human
Services (Australian Government), Australian Institute
of Health and Welfare (Australian Government), SA
Department of Health (South Australian Government),
Queensland Department of Health (Queensland Government),Department of Health Victoria (Victorian Government),
and the Aboriginal Health Research Ethics Committee
(Aboriginal Health Council of South Australia).
Discussion
The DCP is designed to facilitate a robust yet pragmatic
comparison of different, evidence-based models of care in
order to evaluate how care can be improved for people
with diabetes, and to determine the level of change that
would be required to achieve this in the Australian con-
text. Intervention 1 tests the extent to which current re-
forms (such as e-Health and clinical training initiatives)
will improve care for people with diabetes. Intervention 2
tests the impact of altering primary care funding to create
a ‘health care home,’ in which patients voluntarily register
with a practice and are cared for by a multidisciplinary
team coordinated by a care facilitator. Implementing the
‘health care home’ model of care (Intervention 2) at scale
would involve substantial changes to the health system,
and the DCP will therefore evaluate the incremental
benefit of this intervention to ascertain if nationwide
implementation is worthwhile.
A number of steps have been taken to ensure that this
evaluation is rigorous and objective, and to increase the
validity of the project’s final recommendations, including:
introducing as much randomisation as is possible for this
type of complex health reform; choosing populations to be
representative of the Australian general practice landscape;
and ensuring that the size of the trial will allow for testing
of a range of different hypotheses (for example, whether
the interventions work better in small or large practices
and in urban or non-urban areas, and whether they affect
people with more complicated diabetes and people with
less complicated diabetes in different ways).
Two potential drawbacks of the trial design are that
Medicare Locals/Divisions of General Practice only sup-
port one of the two interventions, and that patients are
enrolled after practices have been randomised. It was ne-
cessary to retain both of these design features in order to
make the trial workable. Firstly, requiring practices to sup-
port both interventions would have placed impossible de-
mands on general practitioners, allied health professionals
and Medicare Locals/Divisions of General Practice. The
DCP’s approach means that Medicare Locals/Divisions of
General Practice need only train practices in, and provide
support for, one of the interventions, and any bias between
Medicare Locals/Divisions of General Practice will be
detected and corrected for by the DCP’s evaluation
team. Secondly, postponing randomisation until patient
enrolment was complete would have added a delay of six
months (following initial sign up) for patients starting in
the trial, and would have required control practices to be
trained in the intervention in order for patients to give
informed consent, thus confounding results.
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find practical and workable solutions to improving
diabetes management in Australia that are informed by
front-line experience. The trial has been developed
through consultation with clinicians and patients during
the design phase, and the project receives regular input
from the national Diabetes Advisory Group, which com-
prises seventeen leaders of professional bodies repre-
senting various clinicians and people with diabetes. The
consortium that is delivering the project consists of over
twenty organisations (including Medicare Locals/Divisions
of General Practice, state-based primary care organisa-
tions, state health departments and universities), and
the project runs quarterly feedback forums with partici-
pating clinicians and patients.
The increasing global prevalence of diabetes, and the
accompanying rise in complications and associated excess
morbidity and mortality, suggest that the current approach
to caring for people with diabetes can be improved. As the
largest randomised controlled trial on the management of
diabetes in Australia, the DCP has an opportunity to com-
pare new, evidence-based approaches to diabetes manage-
ment and to identify a model of care that improves health
outcomes and patient and practitioner experiences, is
scalable nationally and is economically sustainable. The
outcomes of the study will have important implications
not only for diabetes management, but also for the
management of other chronic diseases, both in Australia
and overseas.
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